Navigation Links
Aeras awarded €11.7 million ($16 million) grant from Dutch government
Date:11/12/2010

Rockville/Berlin, 12 November 2010 The Aeras Global TB Vaccine Foundation is pleased to announce that the Netherlands Ministry of Foreign Affairs has renewed its funding to Aeras with a pledge of an additional 11.7 million over four years (2011-2014) to further its efforts to develop new vaccines to help combat the global epidemic of tuberculosis.

This expression of support represents a continuation in the long-standing collaboration between the Dutch government, Aeras and its research partners. This is the second grant to Aeras from the Netherlands Ministry of Foreign Affairs, representing a total commitment of 30.4 million to Aeras since 2006.

"The forward movement of TB vaccine candidates in the development pipeline owes a great deal to the generous support of the Dutch Ministry of Foreign Affairs and the people of the Netherlands," said Jim Connolly, President and Chief Executive Officer of the Aeras Global TB Vaccine Foundation. "We are extraordinarily grateful for their foresight and steadfast support of these potentially life saving efforts."

TB is one of the world's deadliest infectious diseases, killing nearly 2 million men, women and children every year. Despite global efforts to prevent and treat TB, the epidemic is becoming more complex and difficult to diagnose and treat due in large part to the emergence of drug-resistant forms of TB and the emergence of the HIV epidemic. TB is responsible for the majority of AIDS deaths in Africa.

New TB vaccines are urgently needed. The currently available vaccine, Bacille Calmette-Gurin, provides some protection against pediatric TB but is unreliable in protecting adult pulmonary TB, the most common form of the disease. As a product development partnership, Aeras collaborates and facilitates research in conjunction with numerous scientists in academic, pharmaceutical, biotechnology and government research centers around the world to develop safer and more immunogenic TB vaccines. Globally, nine TB vaccine candidates are currently undergoing clinical testing, and of those, four are directly supported and led by Aeras and its network.

Since the Netherlands's first grant to Aeras and its partners in 2006, four TB vaccine candidates in Aeras' product portfolio have moved into clinical testing in Europe, North America and Africa. Two of those are at the Phase II proof of concept stage and will enroll infants in South Africa, Kenya, Uganda and Mozambique.


'/>"/>

Contact: Annmarie Leadman
aleadman@aeras.org
Aeras Global TB Vaccine Foundation
Source:Eurekalert

Related biology news :

1. Aeras-led research consortium receives FDA support
2. Mississauga teacher awarded prize for excellence in teaching genomics
3. $1,820,000 from NSF awarded to Rutgers-Newark to acquire fMRI dedicated to research
4. SAIC Awarded $23 Million Task Order by Defense Biometrics Identity Management Agency
5. LSUHSC awarded $12 million for cancer, infectious diseases research & research pipeline
6. OU researchers awarded $3M DOE grant to determine effects of climate change on two ecosystems
7. Rutgers part of team awarded $3.3 million National Institutes of Health grant for prostate cancer research
8. Salk Institute Medals to be awarded to Robert Roeder and Irwin Jacobs
9. 2010 Albert Maucher Prize awarded to Potsdam palaeoclimatologist
10. Researcher awarded $2.27 million to study environmental effects on gene copy number
11. Professor Dr. Alexander (Sandy) Lawson is awarded the 2011 Herman Skolnik Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
(Date:2/9/2017)... Feb. 9, 2017 The biomass boiler market ... the biomass boiler market globally in terms of revenue ... boilers. The market for biomass boilers has been segmented ... application, and country/region. The market based on feedstock type, ... residues, biogas & energy crops, urban residues, and others. ...
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... ... February 27, 2017 , ... In starting a program to hire ... grandfather, “Hire for attitude. Train for skill.” , In keeping with this philosophy, the ... as a salesman. Zamzow is hoping to replicate the practice throughout the company. , ...
(Date:2/24/2017)... SAN FRANCISCO, CA (PRWEB) , ... February 24, 2017 , ... ... awarding of a $224K grant from the National Institute of Mental Health (NIMH) for ... is based on Delpor’s PROZOR technology and is expected to deliver therapeutic ...
(Date:2/24/2017)... , Feb. 24, 2017  Driven by consumers, ... are now the fastest growing categories, finds the ... Actives in Personal Care: Multi-regional Market Analysis and ... management consulting firm Kline. "Biotechnology actives ... make them more effective for skin and hair ...
(Date:2/24/2017)... 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), ... a Key Opinion Leader event to highlight new clinical ... poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium ... will be held in-person and via live webcast on ... AM PST at the Lotte New York Palace Hotel ...
Breaking Biology Technology: